$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

2017 Q2 Form 10-Q Financial Statement

#000114420417025926 Filed on May 10, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $370.0K $180.0K $140.0K
YoY Change 94.74% 28.57% 1300.0%
% of Gross Profit
Research & Development $25.19K $59.83K $4.364K
YoY Change 39.72% 1271.01%
% of Gross Profit
Depreciation & Amortization $10.00K $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $396.0K $240.8K $147.1K
YoY Change 90.29% 63.7% 1371.29%
Operating Profit -$396.0K -$240.8K -$147.8K
YoY Change 89.25% 62.9%
Interest Expense $63.24K $2.505K $0.00
YoY Change 5399.13%
% of Operating Profit
Other Income/Expense, Net -$490.4K -$2.505K
YoY Change 42540.43%
Pretax Income -$886.4K -$243.4K -$150.0K
YoY Change 322.07% 62.23% 1400.0%
Income Tax
% Of Pretax Income
Net Earnings -$886.4K -$243.4K -$147.8K
YoY Change 323.59% 64.6% 1378.45%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$6.255K -$1.736K -$1.500K
COMMON SHARES
Basic Shares Outstanding 106.3M shares 105.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $100.0K $100.0K $0.00
YoY Change 233.33%
Cash & Equivalents $104.4K $98.12K $15.14K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $100.0K $98.12K $0.00
YoY Change 233.33%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $199.6K $98.01K $0.00
YoY Change 117.73%
TOTAL ASSETS
Total Short-Term Assets $100.0K $98.12K $0.00
Total Long-Term Assets $199.6K $98.01K $0.00
Total Assets $299.6K $196.1K $0.00
YoY Change 146.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $53.20K $96.88K $20.00K
YoY Change 107.8% 384.4% 100.0%
Accrued Expenses $9.869K $6.891K
YoY Change 260.71%
Deferred Revenue
YoY Change
Short-Term Debt $270.0K $100.0K $150.0K
YoY Change 285.71% -33.33% 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.314M $468.9K $170.0K
YoY Change 332.17% 175.81% 6.25%
LONG-TERM LIABILITIES
Long-Term Debt $10.00K $30.00K $20.00K
YoY Change -85.71% 50.0%
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $10.00K $30.00K $20.00K
YoY Change -85.71% 50.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.314M $468.9K $170.0K
Total Long-Term Liabilities $10.00K $30.00K $20.00K
Total Liabilities $1.322M $495.8K $190.0K
YoY Change 254.42% 160.95% 18.75%
SHAREHOLDERS EQUITY
Retained Earnings -$1.896M -$1.010M
YoY Change 430.29%
Common Stock $873.7K $710.2K $100.0K
YoY Change 722.57% 610.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.020M -$300.0K -$190.0K
YoY Change
Total Liabilities & Shareholders Equity $299.6K $196.1K $0.00
YoY Change 146.23%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$886.4K -$243.4K -$147.8K
YoY Change 323.59% 64.6% 1378.45%
Depreciation, Depletion And Amortization $10.00K $0.00 $0.00
YoY Change
Cash From Operating Activities -$270.0K -$223.7K -$40.00K
YoY Change 170.0% 459.37% 300.0%
INVESTING ACTIVITIES
Capital Expenditures $100.0K $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$100.0K $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 380.0K $100.0K 50.00K
YoY Change 245.45% 100.0% 400.0%
NET CHANGE
Cash From Operating Activities -270.0K -$223.7K -40.00K
Cash From Investing Activities -100.0K 0.000 0.000
Cash From Financing Activities 380.0K $100.0K 50.00K
Net Change In Cash 10.00K -$123.7K 10.00K
YoY Change 0.0% -1337.49%
FREE CASH FLOW
Cash From Operating Activities -$270.0K -$223.7K -$40.00K
Capital Expenditures $100.0K $0.00 $0.00
Free Cash Flow -$370.0K -$223.7K -$40.00K
YoY Change 459.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 us-gaap Assets
Assets
196126 USD
CY2016Q4 us-gaap Assets
Assets
322512 USD
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
96879 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
66385 USD
CY2017Q1 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
100000 USD
CY2016Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
100000 USD
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6891 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4879 USD
CY2017Q1 us-gaap Management Fee Payable
ManagementFeePayable
262500 USD
CY2016Q4 us-gaap Management Fee Payable
ManagementFeePayable
280000 USD
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
106014 USD
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
105014 USD
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
604233 USD
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
503767 USD
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1009923 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-766572 USD
CY2017Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-299676 USD
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-157791 USD
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
196126 USD
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
468870 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
453864 USD
CY2017Q1 us-gaap Liabilities
Liabilities
495802 USD
CY2016Q4 us-gaap Liabilities
Liabilities
480303 USD
CY2017Q1 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
25000 USD
CY2016Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
25000 USD
CY2017Q1 us-gaap Assets Current
AssetsCurrent
98119 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
221868 USD
CY2017Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
2600 USD
CY2016Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
2600 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
322512 USD
CY2017Q1 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
1932 USD
CY2016Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
1439 USD
CY2017Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
98007 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
100644 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
59831 USD
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
178378 USD
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
240846 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-243351 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-243351 USD
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
105102639 shares
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
CY2017Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2637 USD
CY2016Q1 us-gaap Revenues
Revenues
0 USD
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4364 USD
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
141176 USD
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
147129 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-147845 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-147845 USD
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
73906815 shares
CY2017Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
2505 USD
CY2016Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
716 USD
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1466 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
30494 USD
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2505 USD
CY2017Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-17500 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-223749 USD
CY2017Q1 celz Proceeds From Subscription Receivable
ProceedsFromSubscriptionReceivable
0 USD
CY2017Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
100000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-123749 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
221868 USD
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98119 USD
CY2017Q1 us-gaap Interest Paid
InterestPaid
0 USD
CY2017Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3780 USD
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1800 USD
CY2016Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
105000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-35676 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
50716 USD
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
15040 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15140 USD
CY2016Q1 us-gaap Interest Paid
InterestPaid
0 USD
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
105013750 shares
CY2016Q1 us-gaap Stock Issued1
StockIssued1
100000 USD
CY2017Q1 us-gaap Stock Issued1
StockIssued1
0 USD
CY2017Q1 celz Stock Issued For Purchase Of Technology License
StockIssuedForPurchaseOfTechnologyLicense
0 USD
CY2016Q1 celz Stock Issued For Purchase Of Technology License
StockIssuedForPurchaseOfTechnologyLicense
1000 USD
CY2016Q2 celz Amount Of Debt Payable At Closing
AmountOfDebtPayableAtClosing
20000 USD
CY2016Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
CY2016Q1 celz Proceeds From Subscription Receivable
ProceedsFromSubscriptionReceivable
49500 USD
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
0 USD
CY2016Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1216 USD
CY2017Q1 celz Fair Value Of Warrants Issued In Private Placement
FairValueOfWarrantsIssuedInPrivatePlacement
5546 USD
CY2016Q1 celz Fair Value Of Warrants Issued In Private Placement
FairValueOfWarrantsIssuedInPrivatePlacement
0 USD
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
29427 USD
CY2017Q1 celz Employee Service Sharebased Compensation Nonvested Awards Expiration Period
EmployeeServiceSharebasedCompensationNonvestedAwardsExpirationPeriod
2021
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001187953
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q1 dei Trading Symbol
TradingSymbol
CELZ
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
106263750 shares
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
106013750 shares
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
106013750 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
105013750 shares
CY2017Q1 celz Working Capital Deficit
WorkingCapitalDeficit
370751 USD
CY2017Q1 celz Class Of Warrant Or Right Conversion Ratio
ClassOfWarrantOrRightConversionRatio
one warrant to purchase another share of common stock at $0.10 per share for each ten shares purchased in the offering.
CY2017Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2016Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><strong><i>Use of Estimates</i></strong> - The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
7500 USD
CY2017Q1 celz Success Feepercentage
SuccessFeepercentage
0.06 pure
CY2017Q1 celz Success Feedescription
SuccessFeedescription
Pay a success fee of 10% for equity and/or convertible preferred or debt for the first $5.0 million; 8% for capital raised between $5.0 and $25.0 million and 6% for all amounts raised above $25.0. Upon any financing the agreement will be extended for an additional 24 months at $7,500 per month.
CY2017Q1 celz Business Combination Step Acquisition Payment Percentage
BusinessCombinationStepAcquisitionPaymentPercentage
0.05 pure
CY2016Q2 celz Common Stock Percentage Represents Fully Diluted Amount
CommonStockPercentageRepresentsFullyDilutedAmount
0.005 pure
CY2016Q2 celz Percentage Increase In Fully Diluted Amount Upon Funding
PercentageIncreaseInFullyDilutedAmountUponFunding
0.005 pure

Files In Submission

Name View Source Status
0001144204-17-025926-index-headers.html Edgar Link pending
0001144204-17-025926-index.html Edgar Link pending
0001144204-17-025926.txt Edgar Link pending
0001144204-17-025926-xbrl.zip Edgar Link pending
celz-20170331.xml Edgar Link completed
celz-20170331.xsd Edgar Link pending
celz-20170331_cal.xml Edgar Link unprocessable
celz-20170331_def.xml Edgar Link unprocessable
celz-20170331_lab.xml Edgar Link unprocessable
celz-20170331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v465447_10q.htm Edgar Link pending
v465447_ex10-1.htm Edgar Link pending
v465447_ex31-1.htm Edgar Link pending
v465447_ex31-2.htm Edgar Link pending
v465447_ex32-1.htm Edgar Link pending
v465447_ex32-2.htm Edgar Link pending